Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment

Research output: Contribution to journalReview articlepeer-review

Abstract

The presence of FLT3 mutations in acute myeloid leukemia (AML) carries a particularly poor prognosis, making the development of FLT3 inhibitors an imperative goal. The last decade has seen an abundance of clinical trials using these drugs alone or in combination with chemotherapy. This culminated with the recent approval by the US Food and Drug Administration of Midostaurin for the treatment of FLT3-mutated AML. Initial success has been followed by the emergence of clinical resistance. Although novel FLT3 inhibitors are being developed, studies into mechanisms of resistance raise hope of new strategies to prevent emergence of resistance and eliminate minimal residual disease.

Original languageEnglish (US)
Pages (from-to)681-692
Number of pages12
JournalHematology/Oncology Clinics of North America
Volume31
Issue number4
DOIs
StatePublished - Aug 2017

Keywords

  • AML
  • FLT3 inhibitors
  • FLT3-ITD
  • Stem cell niche

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment'. Together they form a unique fingerprint.

Cite this